Helicobacter pylori and non-malignant diseases

Helicobacter, Supplement

Volumn 10, Issue 1, 2005, Pages 26-33

  Kupcinskas, Limas ^a   Malfertheiner, Peter ^b  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gastro esophageal reflux disease; Helicobacter pylori; Non ulcer dyspepsia; Nonsteroidal anti inflammatory drugs; Peptic ulcer disease; Uninvestigated dyspepsia

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGE; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REVIEW;

HELICOBACTER PYLORI;

EID: 25844471157     PISSN: 14784041     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2005.00340.x     Document Type: Review

References (45)

1. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005;128:833-48.
2. de Jonge R, Kuipers EJ, Langeveld SC, Loffeld RJ, Stoof J, van Vliet AH, Kusters JG. The Helicobacter pylori plasticity region locus jhp0947-jhp0949 is associated with duodenal ulcer disease and interleukin-12 production in monocyte cells. FEMS Immunol Med Microbiol 2004;41:161-7.
3. Lu CC, Sheu BS, Chen TW, Yang HB, Hung KH, Kao AW, Chuang CH, Wu JJ. Host TNF-alpha-1031 and -863 promoter single nucleotide polymorphisms determine the risk of benign ulceration after H. pylori infection. Am J Gastroenterol 2005;100:1274-82.
4. Rosenstock SJ, Jorgensen T, Bonnevie O, Andersen LP. Does Helicobacter pylori infection explain all socio-economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adults. Scand J Gastroenterol 2004;39:823-9.
5. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004;4:CD003840.
6. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005;21:795-804.
7. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;2:CD004062.
8. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of Helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med 2004;116:601-5.
9. Adamopoulos AB, Efstathiou SP, Tsioulos DI, Tzamouranis DG, Tsiakou AG, Tiniakos D, Mountokalakis TD. Bleeding duodenal ulcer: comparison between Helicobacter pylori positive and Helicobacter pylori negative bleeders. Dig Liver Dis 2004;36:13-20.
10. Giral A, Ozdogan O, Celikel CA, Tozun N, Ulusoy NB, Kalayci C. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004;19:773-7.
11. Gisbert JP, Legido J, Garcia-Sanz I, Pajares JM. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis 2004;36: 116-20.
12. Wu CY, Wu MS, Chen CJ, Li MC, Lin JT, Chen GH. The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer. J Clin Gastroenterol 2005;9:50-5.
13. Chang CC, Chen SH, Lien GS, Lou HY, Hsieh CR, Fang CL, Pan S. Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. World J Gastroenterol 2005;11:104-8.
14. Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C, Di Mario F. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:1091-7.
15. Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;1:CD002096.
16. Farkkila M, Sarna S, Valtonen V, Sipponen P, PROSPER Study Group. Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol 2004;39:327-35.
17. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut 2004;53:1758-63.
18. Chiba N, Veldhuyzen Van Zanten SJ, Escobedo S, Grace E, Lee J, Sinclair P, Barkun A, Armstrong D, Thomson AB. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther 2004;19:349-58.
19. Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, McColl KE, Myres P, Delaney BC. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838-44.
20. Talley NJ, Vakil N, Delaney B, Marshall B, Bytzer P, Engstrand L, de Boer W, Jones R, Malfertheiner P, Agreus L. Management issues in dyspepsia: current consensus and controversies. Scand J Gastroenterol 2004;39:913-8.
21. Kapoor N, Bassi A, Sturgess R, Bodger K. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut 2005;5:40-5.
22. Schmidt N, Peitz U, Lippert H, Malfertheiner P. Missing gastric cancer in dyspepsia. Aliment Pharmacol Ther 2005;21:813-20.
23. Bytzer P. Diagnostic approach to dyspepsia. Best Pract Res Clin Gastroenterol 2004;18:681-93.
24. Heikkinen M, Vornanen M, Hollmen S, Farkkila M. Prognostic significance of antrum-predominant gastritis in functional dyspepsia. Scand J Gastroenterol 2004;39:227-31.
25. Pietroiusti A, Luzzi I, Gomez MJ, Magrini A, Bergamaschi A, Forlini A, Galante A. Helicobacter pylori duodenal colonization is a strong risk factor for the development of duodenal ulcer. Aliment Pharmacol Ther 2005;21:909-15.
26. Loffeld RJ, van der Putten AB. Helicobacter pylori and gastro-oesophageal reflux disease: a cross-sectional epidemiological study. Neth J Med 2004;62:188-91.
27. Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek W, Stolte M, Vieth M, Willich S, Malfertheiner P. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-6.
28. Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004;99:1437-41.
29. Jonaitis LV, Kiudelis G, Kupcinskas L. Characteristics of patients with erosive and nonerosive GERD in high-Helicobacter-pylori prevalence region. Dis Esophagus 2004; 17:223-7.
30. Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, Imatani A, Kato K, Shimosegawa T. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol 2004;99:1213-21.
31. Weston AP, Sharma P, Mathur S, Banerjee S, Jafri AK, Cherian R, McGregor D, Hassanein RS, Hall M. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004;99:1657-66.
32. Kudo M, Gutierrez O, El-Zimaity HM, Cardona H, Nurgalieva ZZ, Wu J, Graham DY. CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer. J Clin Pathol 2005;58:259-62.
33. Queiroz DM, Guerra JB, Rocha GA, Rocha AM, Santos A, De Oliveira AG, Cabrai MM, Nogueira AM, De Oliveira CA. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology 2004;127:73-9.
34. Jakobs R, Riemann JF. cvzgA-positive Helicobacter pylori strains and gastro-oesophageal reflux disease: still puzzling? Eur J Gastroenterol Hepatol 2004; 16:635-7.
35. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P; Bristol Helicobacter Project. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. BMJ 2004;328:1388-9.
36. Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, Chung SC, Sung JJ. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004;53:174-9.
37. Kuipers EJ, Nelis GJ, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
38. Ott EA, Mazzoleni LE, Edelweiss MI, et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther 2005;21:1231.
39. Kupcinskas L, Jonaitis L, Kiudelis G. A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased prevalence of non-erosive gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2004;16:369-74.
40. Yamamori K, Fujiwara Y, Shiba M, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Higuchi K, Arakawa T. Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2004;20(Suppl 1):107-11.
41. Peitz U, Raps S, Plein K, Leodolter A, Hotz Dagger J, Malfertheiner P. Long-term course of reflux symptoms following Helicobacter pylori eradication. Dtsch Med Wochenschr 2004;129:671-5.
42. Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733-44.
43. Inoue H, Imoto I, Taguchi Y, Kuroda M, Nakamura M, Horiki N, Oka S, Gabazza EC, Adachi Y. Reflux esophagitis after eradication of Helicobacter pylori is associated with the degree of hiatal hernia. Scand J Gastroenterol 2004;39:1061-5.
44. Fallone CA, Barkun AN, Mayrand S, Wakil G, Friedman G, Szilagyi A, Wheeler C, Ross D. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004;20:761-8.
45. Axon AT. Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease - an alternative hypothesis. Aliment Pharmacol Ther 2004;19:253-61.